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ABSTRACT: Lung cancer is by far the leading cause of cancer 
death among both men and women. Screening patients at high 
risk of developing lung cancer is a worldwide priority, since it 
can be cured if diagnosed in early stages. Currently, screening 
in high risk individuals is made using low dose computed 
tomography, however, this method may lead to false-positive tests 
and overdiagnosis. The usefulness of serum biomarkers would 
be relevant in two situations: 1) the screening of large groups at 
high risk of developing lung cancer, where the biomarker should 
be very sensitive and 2) during the investigation of pulmonary 
nodules, where the biomarker should be very specific. Several 
serum biomarkers have been tested to work as biomarkers for lung 
cancer screening. Unfortunately, so far, none of them has come 
into current clinical practice. In this review, we analyze some of 
the serum biomarkers described in the last 10 years, evaluating 
their potential as tools to detect lung cancer, particularly in 
smokers. The use of serum biomarkers and imaging methods 
together seems to be a solution to early diagnosis of lung cancer, 
more efficient treatment and enhanced chance of cure.
Keywords: Biomarkers; Early diagnosis; Tobacco use disorder; 
Carcinoma, non-small-cell lung; Neoplasias pulmonares/
diagnóstico; Neoplasias pulmonares/diagnóstico por imagem.
RESUMO: O câncer de pulmão é de longe a principal causa 
de morte por câncer entre homens e mulheres. A triagem de 
pacientes com alto risco de desenvolver câncer de pulmão é uma 
prioridade mundial, já que pode ser curado se diagnosticado em 
estágios iniciais. O rastreio em indivíduos de alto risco é feito 
usando tomografia computadorizada de baixa dose, no entanto, 
este método pode levar a testes falso-positivos e diagnósticos 
equivocados (“overdiagnosis”). Vários biomarcadores séricos 
foram testados para funcionar como biomarcadores para o 
rastreamento do câncer de pulmão. Infelizmente, até agora, 
nenhum deles entrou na prática clínica. Nesta revisão, analisamos 
alguns dos biomarcadores séricos descritos nos últimos 10 anos, 
avaliando seu potencial como ferramentas para detectar câncer 
de pulmão, particularmente em fumantes. A utilização de um 
biomarcador ou de um painel de biomarcadores seria relevante 
em duas situações: 1) triagem de grandes grupos de indivíduos 
com alto risco de desenvolver câncer de pulmão, para o qual o 
biomarcador deve ser muito sensível, e 2) durante a investigação 
de nódulos pulmonares, em que o biomarcador deve ser muito 
específico. Portanto, o uso combinado de biomarcadores séricos 
e métodos de imagem parece ser uma solução para o diagnóstico 
precoce do câncer de pulmão e, consequentemente, para um 
tratamento mais eficiente e maior chance de cura.
Descritores: Biomarcadores; Diagnóstico precoce; Tabagismo; 
Carcinoma pulmonar de células não pequenas; Neoplasias 
pulmonares/diagnóstico; Neoplasias pulmonares/diagnóstico 
por imagem.
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INTRODUCTION
Epidemiology of lung cancer 
In most of the Western countries, cancer ranks the second most common cause of death following 
cardiovascular diseases. Tens of millions of people are 
diagnosed with cancer each year, and more than half of 
the patients will eventually die from it1.
Lung cancer is particularly important. With an 
increasing incidence every year2, it has the second higher 
incidence among males (behind prostate cancer) and 
females (behind breast cancer). However, it ranks first in 
mortality in both genders.
In Brazil, the National Cancer Institute (INCA), 
estimated the diagnosis of 18,740 new cases in men 
and 12,530 in women during the year 20184. Moreover, 
according to data from the Mortality Information System 
(SIM), lung cancer accounted for more than 26,000 deaths 
in the year 20154.
As the majority of other cancer types, lung tumors 
derive from synergy between genetic and environmental 
risk factors5; among the latter, smoking has been 
described as the most important risk factor for lung cancer 
development6. Other risk factors, such as occupational 
chemical exposures (asbestos, for example), environmental 
exposure to radon, personal and family history, are also 
recorded in the literature7.
About 90% of lung cancer cases are related to 
tobacco inhalation8. Smoking itself increases the risk of 
lung cancer 5 to 10 times, presenting a significant dose-
response relationship. Not only active smoking, but also 
passive smoking is a risk factor for lung cancer, and 
exposure to tobacco accounts for about 20% of cases in 
nonsmokers3,6,8-10.
Regarding the histopathological aspect, lung cancer 
is more commonly subdivided as small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC)7,11. In 
the present review, only NSCLC will be addressed, since 
it is the most common type and its relationship to smoking 
is better characterized.
Since lung cancer leads to death in a high percentage 
of the patients suffering from this condition, it is crucial 
to improve its early detection, when therapeutics is still 
curative and effective.
Screening for early lung cancer
The first large scale study for lung cancer screening 
was performed by the Mass Radiography Service of the 
North-West Metropolitan Region of London, in the 1960s12. 
It was a prospective study without randomization, where 
the test group, composed by 29,723 men, were submitted 
to chest radiograph exams (CXR) every six months for 
three years. In parallel, a control group, with 25,311 men, 
were radiographed at the beginning and at the end of the 
study, after three years. Lung cancer was diagnosed in more 
patients in the test group compared to the control group 
(132 vs. 96, respectively), however, there was no change in 
mortality between groups (62 vs. 59, respectively). Despite 
the absence of results in reducing mortality, this study 
was enough to encourage high-risk groups to be screened 
regularly since it showed success for the discovery of 
surgically approachable lung cancers.
In the 1990’s, improvements in computerized 
tomography scanners brought back the interest in screening 
for lung cancer. The Early Lung Cancer Action Project 
(ELCAP) was designed to evaluate the usefulness of CT 
in annual lung cancer screening13. The ELCAP obtained 
chest radiography and low-dose CT (LDCT) of 1,000 
asymptomatic individuals, 60 years old or more, with 
smoking history of at least 10 pack-years. The low-dose 
CT was more efficient in the detection of noncalcified 
pulmonary nodules (NCN) than the CXR (23% versus 
7%, respectively) and identified the disease in earlier and 
curable stages (often stage I).
On the other side, this screening method was 
criticized for the potential overdiagnosis of small lesions 
that would not fully develop into symptomatic tumors. In 
order to avoid it, pathologic criteria were carefully used, 
and an analysis of the histologic specimens from surgeries 
was done to confirm the previous lung cancer diagnosis. 
Based on ELCAP and other similar projects, the proportion 
of overdiagnosis could be empirically estimated. These 
findings were further confirmed by other studies with 
high-risk groups14.
These studies showed that LDCT was adequate to 
identify early lung nodules, but none of them was capable 
of demonstrating reductions in mortality related to lung 
cancer. Hence, a large randomized controlled trial was 
performed, the National Lung Screening Trial (NLST). In 
this trial, 53,456 participants underwent screening from 
2002 to 2004. This study demonstrated a 20% reduction 
in disease-specific mortality when low-dose CT (LDCT) 
was used, compared to chest radiography10.
These  f ind ings  p rompted  the  Na t iona l 
Comprehensive Cancer Network (NCCN) to release their 
guidelines for lung cancer screening in 201515, with an 
algorithm to calculate lung cancer risk and indications 
for CT screening (Figure 1). Smoking history, radon 
exposure, occupational exposure, cancer history, family 
history of lung cancer, pulmonary disease history, smoking 
exposure and absence of symptoms or signs of lung cancer 
are relevant factors to differentiate the groups. Patients 
included in the high-risk group are recommended to 
undergo screening routinely. In case of nodule detection, 
the algorithm shown in Figure 2 should be followed.
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Adapted from: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening V.1.2015.
Figure 1: Algorithm for calculating risk of lung cancer and indications for screening
Adapted from: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening V.1.2015.
Figure 2: Algorithm to investigation of lung nodule detected at CT screening
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The American Associat ion for  Thoracic 
Surgery Guidelines Task Force has also released their 
recommendations to indicate screening with annual LDCT, 
which are summarized in Figure 316.
Adapted from: Stiles BM et al. Surgical Oncology Clinics of North America. 2016 Jul;25(3):469-79 (16)
Figure 3: American Association for Thoracic Surgery recommendations for CT screening for lung cancer 
Although the current data show reduced mortality 
in patients that underwent LDCT screening, particularly 
due to early surgery to remove suspect nodules, there is 
still several concerns, mainly about false-positive tests, 
overdiagnosis and their complications17.
LDCT is not a very specific method, with a high 
incidence of false-positive diagnoses; these patients 
are, then, usually submitted to invasive procedures 
to confirm the diagnosis of cancer (mediastinoscopy, 
thoracoscopy, thoracotomy, bronchoscopy or needle 
biopsy), and complications may arise.  Moreover, this kind 
of investigation can have deleterious effect in patients’ 
mental and physical health, before the cancer diagnosis 
could be dismissed18.
In addition, increasing exposure to ionizing 
radiation from CT screening is also relevant. The amount of 
radiation in the LDCT is very low, however the repeatedly 
exposure that the annual screening demands may be 
clinically relevant, due to its carcinogenic potential19.
As summary, LDCT screening has proved to 
be a valuable tool for identifying small nodules and, 
consequently, lung cancer in early stages. Unfortunately, 
this method is not highly specific. Therefore, a non-
negligible number of patients are submitted to invasive 
procedures and have a benign histopathological diagnosis. 
This high incidence of false-positive CTs may lead to 
undesirable invasive procedures and implies in higher costs 
to the whole health system20.
Serum biomarkers for lung cancer screening
LDCT is the method recommended by the recent 
guidelines to identify early lung nodules but has several 
pitfalls that points out the necessity to improve or replace 
it by less invasive methods that might offer a better cost-
effectiveness relationship18-21.
Biomarkers are parameters that can be objectively 
measured aiming to detect a physiological or pathological 
process22. Biomarkers can be useful for screening, 
diagnosing, staging or classifying a particular disease, 
as well as to give a prognosis and to monitor the clinical 
response to an intervention. They are also a potential tool 
to provide information about diseases pathophysiology.
Cancer biomarkers are already being used for 
screening and diagnosis, such as the prostate-specific 
antigen (PSA) for prostate cancer23, genetic alterations 
(BRCA mutations) for breast cancer24 and the presence of 
occult blood in the stool for colorectal cancer25.
Serum biomarkers for lung cancer screening would 
be less invasive, exposing patients only to minimal risks and 
they should reflect pathophysiology mechanisms, leading 
to lower rates of overdiagnosis and false-positives. Beyond 
that, serum biomarkers could be more accurate when 
allied to the LDCT regarding the indication of invasive 
procedures, such as biopsies.
These biomarkers must have specific properties to be 
considered suitable for screening and diagnosis: they must 
be involved in carcinogenesis, may be modulated according 
to disease progression, and be associated with risk factors26. 
Once a biomarker complies with these properties, it may 
help to more accurately evaluate a disease.
Therefore, in this review, we summarize some of 
the serum biomarkers that have been studied as potentially 
useful for screening lung cancer in smokers, a group of 
patients at high risk to develop the disease. We focused 
our research in the last ten years literature about serum 
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biomarkers and did not evaluate studies that show possible 
genetic traits related to lung cancer.
METHODOLOGY
This study is a non-systematic review, performed to 
identify published studies that describe serum biomarkers 
of lung cancer.
A single database was used, PubMed, accessed 
during October 2016. The terms used for the search were 
“lung cancer” AND “biomarker” AND (smoker OR 
smoking OR tabagism).
Initially 306 articles were retrieved, and filters were 
applied: “humans”; “adults older than 19 years”; “date of 
publication the past 10 years”; “English or Portuguese 
language”. After this procedure, 138 articles were obtained 
(Figure 4).
The authors, then, analyzed each article by title and 
abstract. Articles identified as reviews, articles focused on 
prognostic or other risk factors different from smoking, 
sources of biomarkers other than serum, and papers about 
genetic mutations that cause lung cancer were excluded.
Therefore, 30 articles were included in our review 
and were carefully analyzed. The selected articles were 
divided by the three main authors who read the articles and 
discussed them with the other authors. Table 1 lists all the 
articles analyzed, while in Results those describing more 
promising biomarkers are discussed in detail.
RESULTS
Thirty articles describing serum biomarkers for 
screening lung cancer were evaluated, as shown in Table 
1. We divided the serum biomarkers described in each 
article by their biochemical characteristics: proteins and 
specific antibodies against antigens expressed by some 
tumors, micronutrients and metabolites, and nucleic acids, 
as miRNAs and DNA modifications. Some of them are 
discussed below.
 Initial search in PubMed 
(n=306) 
Eligible studies 
(n=138) 
Reviewed studies 
(n=30) 
Exclusion by filters 
(n=168) 
Exclusion after reading the abstract, for not 
complying with the main objective: 
- identified as reviews 
- articles focused on prognostic  
- other risk factors different from smoking 
- sources of biomarkers other than serum 
- papers about genetic mutations that cause 
lung cancer  
(n=108) 
Figure 4. Flowchart describing the studies selection
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Table 1: Biomarkers for screening of lung cancer evaluated in this review
Author, Year Biomarker Number of patients Summary Comments
Ho et al., 201631 Insulin and IGFBP3 1143 cases; 1143 controls Insulin and IGFBP3: the combination of these biomarkers could be used for screening.
The sample was composed by postmenopausal 
women.
Guo et al., 201332 Insulin-Like Growth Factor Binding Protein-2 164 cases; 80 controls
Higher serum IGFBP2 levels in patients with 
lung cancer. In addition, this serum biomarker 
correlates with clinical and prognostic outcomes.
Alone, the biomarker IGFBP2 is not a sufficient 
diagnostic value, since sensitivity and specificity 
have been around 70%.
Sin et al., 201335 Pro-surfactant protein B (pro-SFTPB) 2,485 individuals
Lung cancer tumor cells (mainly 
adenocarcinomas) have dysregulated Pro-
surfactant protein B synthesis leading to the 
overexpression of it.
Lack of specificity, pro-SFTPB can also rise in 
other lung diseases.
Taguchi et al., 
201336
Pro-surfactant protein B 
(pro-SFTPB) 188 cases; 337 controls
Levels of circulating mature Pro-surfactant 
protein B were increased among subjects with 
lung cancer both at the time of diagnosis and in a 
pre-diagnostic setting.
Nonspecific - it indicates a pulmonary disease. 
The sample was composed just by men.
Wikoff et al., 
201537
Serum Diacetylspermine + 
Pro-Surfactant Protein B 208 cases; 415 controls
DAS presented an AUC = 0,657 and pro-SFTPB 
presented an AUC = 0,682. Combined, the total 
AUC = 0,808.
Nonspecific - it indicates pulmonary disease. 
Shiels et al.  
201340 C-reactive protein (CRP) 526 patients; 592 controls
Elevated C-reactive protein (CRP) levels were 
associated with a two-fold increased risk of 
lung cancer. Cigarette smoke itself can lead to 
pulmonary inflammation. 
Nonspecific - Serum CRP levels reliably indicate 
the presence of chronic inflammation (not specific 
for lung inflammation).
Xu et al., 201341 CRP 96 cases; 124 controls
SNPs associated with CRP level, but not at risk; 
higher risk for high CRP levels. OR 2.11 for 
CRP> 5.5.
CRP is an extremely nonspecific marker.
Diamandis et al., 
201143
Pentraxin-3; human kallikrein 
11 (KLK11) and progranulin
203 patients, 180 heavy 
smokers, 43 other cancers
Only pentraxin-3 was able to distinguish high risk 
individuals from lung cancer patients, with 48% 
sensitivity and 80% specificity. Using specificity 
of 90%, sensibility declines to 25%.
Pentraxin may be elevated in inflammatory 
conditions.
Lee et al., 201144 CTAP III 30 patients, 30 high-risk individuals
CTAP III is significantly higher in lung cancer 
patients. Small sample.
Yee et al., 200945 CTAP III 16 (1st phase) and 64 (2nd phase)
CTAP III is significantly higher in lung cancer 
patients and is a good predictive tool, when 
associated to other methods. 
Small sample.
Sen et al., 200847 EMAP II 48 cases; 30 controls
Levels of EMAP II are higher in patients with 
lung cancer, but it is not able to distinguish high 
risk group.
Small sample and it is a marker of prognosis, 
more than diagnosis. 
Liu et al., 201249 Antibody anti-ABCC3 275 patients ABCC 3 was significantly higher only in women with adenocarcinoma. The result shows restrict use of the biomarker. 
Rom et al., 201050 Antibodies anti-TAAs 194 patients
A panel of autoantibodies is used to distinguish 
healthy controls, high risk and lung cancer and the 
groups have significant differences.
The sample is too small (only 22 cancer patients).
Chen et al., 201651 Anti-CD25 autoantibody 111 cases; 216 controls Higher levels of Anti-CD25 IgG in patients with stage IV NSCLC only; not useful for early stages
The observations obtained suggest a more 
prognostic biomarker than a diagnostic
Church et al., 
200952 NNAL and PheT 100 cases; 100 controls
Total NNAL in serum is significantly associated 
with lung cancer risk. Nonspecific.
Epplein et al., 
200954 Antioxidant biomarkers 207 cases; 414 controls
Association between increasing levels of serum 
carotenoids and a reduced risk of lung cancer 
in men.
The biomarkers used are nonspecific for lung 
cancer; the results of this study diverge from 
other studies.
Lee et al., 201455 Reactive oxygen species modulator 1 (Romo1) 58 cases; 118 controls
Romo1 expression is higher in NSCLC than in 
controls. For a corset of 329.7pg / mL, sensitivity 
of 81.9% and specificity of 89.8%, AUC of 0.847.
ROMO1 may be elevated in other pulmonary 
diseases.
Chen et al., 201257 10 miRNAs 400 cases; 220 controls
It is possible to distinguish cases and controls 
based in a panel of 10 miRNAs, with 93% 
sensibility and 90% specificity. 
Promising as a screening method. Calibration of 
the quantitative PCR method is a concern
Levine et al., 
201560
DNA methylation levels at 
CpG dinucleotides
2029 participants; 43 lung 
cancer incidences
Having an aging acceleration rate observed by 
the levels of DNA methylation is associated with 
a 2.5-fold increase in the risk of developing lung 
cancer (smoking is seen as a pro-aging factor.
Nonspecific - the methylation was evaluated in 
blood cells; the sample was composed by women; 
the predictability is more sensitive for individuals 
aging 70 years and older; the IEAA has no 
connection to the exposure (tobacco).
Zhang et al., 
201561 F2RL3 methylation
4987 participants; 97 lung 
cancer incidences
F2RL3 hypomethylation was strongly associated 
with both lung cancer incidence and mortality. 
An overexpression of PAR-4 was associated with 
significantly shorter 3-year survival.
Nonspecific - the methylation was evaluated in 
blood cells; the predictability is more sensitive for 
individuals aging 65 years and older.
Greenberg et al., 
200764
S-adenosylmethionine 
(AdoMet) 68 patients
Plasma AdoMet levels had difference between 
lung cancer, high risk and controls. This may be a 
useful tool for the diagnosis of early lung cancer, 
in combination with chest CT.
Nonspecific, difficult to measure, small sample.
Seow et al., 201466 Telomere length in white blood cells 847 cases; 847 controls
The effect of long telomere length in white blood 
cells and lung cancer is particularly evident for 
adenocarcinoma, and especially among women.
Nonspecific - the length of the telomeres can 
indicate different types of cancer; the study was 
performed using white blood cells.
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Author, Year Biomarker Number of patients Summary Comments
Aujollet et al., 
201068 NTproBNP 439 patients
Patients with lung cancer have higher chances of 
increased levels of NTproBNP.
The objective is to analyze other causes to high 
levels of the marker.
Köhler et al., 
201669
Circulating U2 small nuclear 
RNA fragments 211 cases; 112 controls
RNU2-1f expression levels were elevated in 
patients with LC patients treatment naive, 
compared to controls.
More useful as a prognostic and follow-up 
biomarker.
Gumireddy et al., 
201570 AKAP4 264 cases; 135 controls
In the combined cohort, the AKAP4 relative value 
of -4.3 distinguished cases from controls with an 
AUC = 0,9714. Also, distinguished NSCLC from 
benign pulmonary nodes with an AUC = 0,9825 
and accuracy = 93,5%.
Promising as a tool to identify lung cancer from 
benign nodules. Low sensitivity.
Seder et al., 201571 Angiogenesis growing factors 193 cases; 110 controls
Differences in the concentrations of HB-EGF, 
EGF, VEGF-A, VEGF-C E VEGF-D were 
strongly significant (p<0,001), while differences 
in the concentrations of folistatin, PLGF e BMP-9 
were significant (p<0,05).
There was no control of some covariables, such as 
tobacco history.
Doseeva et al., 
201572
Panel of 3 tumor antigens 
(CEA, CA-125, and CYFRA 
21-1) and 1 autoantibody 
marker (NY-ESO-1)
Training set: 115 cases; 
115 controls. Validation 
set: 75 cases; 75 controls
Training set:  in the individual analysis of each 
biomarker, UAC ranged from 0,60-0,79, with 
CEA being the largest (0,79). The combined panel 
had AUC of 0,83. Validation set: UAC 0.81. For 
a cutoff value of 6.4, it resulted in a sensitivity of 
71% and a specificity of 88%. VPN of 99.4% and 
VPP of 7.2%.
Healthy controls? It did not include in the analysis 
benign pulmonary diseases or indeterminate 
nodules. In addition, it does not present the 
expected distribution of types of cancer, stages, 
etc.
Li et al., 201573 Mesenchymal-epithelial transition factor (MET) 95 cases; 44 controls
Serum MET is higher in patients with LC 
compared to controls. MET is even higher in 
patients with higher smoking load, squamous 
cell carcinoma, advanced staging. Sensitivity of 
72.6% and specificity of 90.9%.
MET levels may be higher in patients with other 
tumors.
 Zhang et al., 
201474
Lemur tyrosine kinase-3 
(LMTK3) 524 cases; 380 controls
AUC 0.701. In addition, patients with LMTK3> 
6.85 presented lower survival, correlating with 
prognosis as well.
It did not present a high AUC to be considered a 
diagnostic marker by itself, perhaps it could be 
associated with other biomarkers. It’s more for a 
prognostic marker.
Weber et al., 
201375
RNA MALAT1 
(metastasis-associated lung 
adenocarcinoma transcript 1)
45 cases; 25 controls NSCLC: AUC 0.79; AdCa: 0.75; Squamous cell carcinoma: 0.82; AdCaxSCC: 0.58. Small sample, no high-risk patient was evaluated.
Table 1: Biomarkers for screening of lung cancer evaluated in this review             continuation
Proteins
Insulin and Insulin-like growth factor binding 
protein 3 (IGFBP3)31,32
Smoke produced by tobacco cigarettes induces 
a state of chronic inflammation8. It is well known that 
chronic inflammatory process is usually associated with a 
reduction in the insulin peripheral sensitivity, inducing a 
hyper insulinemic status27-29. Insulin is a potent mitogen that 
activates the Ras/MAPK and PI3K pathways. Therefore, 
hyperinsulinemia can induce cell proliferation that is 
associated with the pathogenesis of lung cancer29.
Insulin-like growth factor binding protein 3 
(IGFBP3) is part of a family of proteins that serve as 
carriers for insulin-like growth factors (IGF), enhancing 
their circulating half-life and modulating their activity30. 
It has been reported that IGFBP3 prevents the activation 
of the IGF1-induced Ras/MAPK pathways, inhibiting its 
inflammatory and proliferative actions30, hence acting as 
an antitumorigenic molecule. 
In a well-designed case-control study31 it was 
observed in current smokers that high serum levels of 
insulin and low levels of IGFBP3 were strongly associated 
with lung cancer. Serum IGF1 was also associated with 
lung cancer, however, only moderately. The authors 
speculated that, among current smokers, both insulin and 
IGF1 activates proliferative pathways, increasing the 
susceptibility to lung cancer. In the other hand, the IGFBP3 
suppresses these pathways, reducing the risk of lung cancer. 
Interestingly, authors observed that the effect of insulin in 
the lung carcinogenesis does not hold a relationship with 
obesity development.
Pro-Surfactant Protein B (pro-SFTPB)35, 36, 37
The pro-surfactant protein B, precursor of protein 
B, is a hydrophilic 42-kD protein produced by type 2 
pneumocytes and non-ciliated bronchiolar cells33. Lung 
tumors, particularly adenocarcinomas, overexpress pro-
SFTPB with a muted ability to turn into the mature form34.
In a prospective study, 2,485 individuals (older than 
50 years old) with high risk for lung cancer (2,237 of them 
were smokers) were followed for at least 2 years and 144 
(5.79%) of them developed the disease. It was observed that 
higher levels of plasma pro-SFTPB, collected at baseline, 
were significantly and independently associated to presence 
of lung cancer in smokers. This phenomenon increments 
the lung cancer prediction calculated by established risk 
factors35. In another study from the same group, it was 
also noticed that, paradoxically, non-detectable levels of 
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pro-SFTPB were significantly associated with lung cancer 
risk in never smokers36. 
Although this protein seems to be suitable as a 
cancer biomarker, it can also be and indicator of other lung 
diseases, such as chronic obstructive pulmonary disease 
(COPD), what limits its clinical usefulness.
C-reactive protein (CRP)40, 41
C-reactive protein (CRP) is a circulating protein 
largely used in the clinical set as a marker on systemic 
inflammation38. High serum levels of CRP have also been 
identified in various types of cancer39. 
In a nested case-control study, 526 lung cancer 
patients were matched to 592 control subjects and 77 
inflammatory mediators were evaluated40. CRP proved to be 
the most discriminatory of these (with an odds ratio around 
2.2). However, association of inflammatory chemokines 
and cytokines with CRP seemed to be more effective as 
biomarkers for lung cancer risk among smokers.  
Despite this strong association, high serum levels 
of CRP can also be found in inflammatory lung conditions, 
such as COPD and pneumonias. Hence, this lack of 
specificity limits the use of CRP as a valid biomarker for 
lung cancer screening, unless it is used in combination with 
other more specific biomarkers. 
Pentraxin-3 (PTX3)43
Several proteins expressed by NSCLC cells in 
culture were identified by a proteomics analysis42. Three of 
these proteins were tested in samples from 203 patients with 
lung cancer, 180 heavy smokers and 43 patients with cancer 
in other locations43. Human kallikrein 11 and progranulin 
showed to be no informative about cancer. Pentraxin-3, 
however, was a significant lung cancer biomarker, with 
considerable ability to separate lung cancer patients 
from high- risk controls. At 90% and 80% specificity, the 
sensitivity versus the high-risk and control group were 37% 
and 48%, respectively. Pentraxin-3 is a protein associated to 
resistance to pathogens and could be elevated in infections, 
sepsis and other malignancies. Due to its high specificity, 
PTX3 would be a very interesting biomarker to differentiate 
lung cancer from benign pulmonary nodules, however, no 
study so far has used it in a clinical set.
Connective Tissue-Activating Peptide III (CTAP 
III)44,45
Connective Tissue-Activating Peptide III (CTAPIII) 
is a chemokine related to angiogenesis and tumorigenesis 
and was reduced in peripheral blood after surgical resection 
of the tumor. Using a different approach, Lee et al.44 
evaluated plasma from 30 patients with lung cancer and 
30 high-risk individuals using Protein Chip immunoassays. 
They identified elevation of CTAP III plasma levels in 
patients’ group. Further, they confirmed this hypothesis 
using an ELISA test in the same population.
In a previous study, it was shown that CTAP III 
serum levels are increased in patients with lung cancer 
and decrease after the tumor resection45. Unfortunately, 
both studies enrolled a small number of patients with 
lung cancer30,49 and no information was provided about 
histology or follow up of these patients. However, due to 
its specificity and relation to cancer pathogenesis, CTAP 
III persists as an intriguing possibility as a lung cancer 
biomarker.
Endothelial monocyte-activating polypeptide-II 
(EMAP II)47
Endothelial monocyte-activating polypeptide-II 
(EMAPII) is a cytokine that has the ability of inhibiting 
angiogenesis, markedly in solid tumors46. The mean 
EMAPII serum levels were found to be significantly 
higher in patients’ population with untreated NSCLC 
than the detected in the control group47. Serum levels 
had no significant association with various clinical or 
pathological features (age, smoking history, performance 
status, histopathology, tumor stage, lymph node stage, 
or distant metastasis). However, the authors reported a 
potential prognostic value, since higher levels were related 
to poor prognosis.
Even though the difference was significant between 
patients and controls, this marker could not detect the early 
stages of the tumor, what limited its use as a screening 
instrument.
Anti-ATP-binding cassette C3 (Anti-ABCC3)49
ATP-binding cassette C3 (ABCC3) is an ATP-
dependent transporter that functions as an energy- driven 
pump to maintain intracellular drug concentrations below 
a toxic level. Therefore, they are one of the main pathways 
responsible for tumor multidrug resistance48. Since this 
class of transporters is usually overexpressed by tumors, 
it is reasonable to conceive that antibodies against them 
might signal the presence of tumors.
Analyzing 178 men and 97 women diagnosed with 
lung cancer (adenocarcinoma or squamous carcinoma), 
authors found that the concentration of IgG against 
ABCC 3 was significantly higher only in women with 
adenocarcinoma49. This finding restricts its use as a 
biomarker and suggests that it would be useful only in a 
panel of autoantibodies, to increase the sensibility of the 
test. 
Anti-tumor associated antigens (Anti-TAAs)50
Sera from lung cancer patients contain autoantibodies 
that react with tumor associated antigens (TAAs) and reflect 
genetic over-expression, mutation, or other anomalies of 
cell cycle, growth, signaling, and metabolism pathways. 
Following previous studies that identify some of 
these TAAs, a study was designed to evaluate whether a 
panel containing ten antibodies against TAAs was able to 
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differentiate lung cancer form other more benign nodules 
found on computed tomography50. They examined the 
sera from lung cancer patients (22 subjects); smokers with 
ground-glass opacities (GGOs) (46 subjects), benign solid 
nodules (55 subjects), or normal CTs (35 subjects); and 
normal non-smokers (36 subjects). The authors reported 
a high specificity for distinguishing patients with lung 
cancer from smokers with normal CTs, stable solid nodules, 
ground glass opacities, or normal healthy never smokers.
Although promising, the study sample was small, 
and no follow-up of the control groups was provided. 
Micronutrients and metabolites
There are some circulating molecules that can also 
have a strong association with lung cancer, such as tobacco-
specific carcinogens and antioxidants.
Tobacco-specific carcinogen52
Among the many known carcinogens in cigarette 
smoke, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) is specific to tobacco and causes lung cancer in 
laboratory animals. Exposure to NNK can be measured by 
serum levels of its metabolites, 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol and its glucuronides (total NNAL). 
Therefore, authors evaluated sera from 100 lung cancer 
patients and 100 matched controls for the presence 
of NNAL. It was reported that serum total NNAL is 
significantly associated with lung cancer risk, particularly 
among long-term heavy smokers52. Besides that, there is a 
positive correlation between serum levels of total NNAL 
and the presence of lung cancer. Therefore, NNAL may 
be a valid biomarker of cigarette smoke exposure and 
consequently, of risk for lung cancer development.
Antioxidants54, 55
Some experimental works have demonstrated a 
relationship between disruption of redox signaling and 
carcinogenesis53. Epplein et al studied the association 
between circulating levels of antioxidants, such as 
carotenoids, tocopherols and selenium, and the presence 
of lung cancer54. It was found a strong inverse association 
between lung cancer risk and total plasma carotenoid 
levels, albeit only in male individuals. No other more 
specific marker of redox signaling dysfunction could be 
associated with the disease. Moreover, there were no other 
relevant data that can corroborate the use of antioxidants 
as biomarkers for lung cancer screening.
Nucleic acids
MicroRNA (miRNA)57
Micro (mi)RNAs are small RNA species that have 
an expression frequently dysregulated in cancer. Several 
studies have focused on the relationship between circulating 
miRNAs and cancer56.
Using samples from 200 lung cancer patients and 
comparing them to 110 healthy controls, Chen et al. found 
10 miRNAs differentially expressed from the 91 miRNAs 
initially tested. Further, these 10 miRNAs were tested in 
a distinct sample of patients and controls, confirming the 
initial findings. Finally, the authors obtained serum samples 
from 20,000 individuals who participated in a community-
based screening program and tested for the panel of 10 
miRNAs. Seven of these individuals had lung cancer during 
the medical follow-up and the miRNAs panel was capable 
of identify six of these seven patients, almost 3 years before 
the diagnosis was made57.
These data are very encouraging, since identification 
of miRNAs is performed by quantitative PCR, an 
inexpensive and disseminated method.
DNA methylation60,61,64
DNA methylation is an epigenetic mechanism 
that controls the activity of genes and is supposed to play 
an important role in carcinogenesis58. It has also been 
described that specific methylated motifs may be used to 
identify the aging process59.
Based on this premise, Levine et al. studied DNA 
methylation levels at CpG nucleotides in circulating 
leukocytes of patients with lung cancer60. DNA methylation 
was classified as positive whether the patient expresses 
a DNA methylation higher than it would be expected 
according to the individual chronological age; the negative 
value expresses a DNA methylation lower than the 
expected. The smoking history was not taken into account 
in this study.
It was observed that one standard deviation above 
the mean indicated a 2.5-fold increased risk of lung 
cancer. Despite the association found, the use of DNA 
methylation in a blood cell can indicate an increased risk 
of cancer in different tissues, not only in the lung tissue, 
what demonstrates the non-specificity of this biomarker60.
Methylation of a specific gene, F2RL3, was 
also studied61. F2RL3 gene codifies the production of 
the coagulation factor II receptor-like 3, also known as 
protease-activated receptor-4 (PAR4), a thrombin receptor, 
part of the G-protein-coupled receptor subfamily that plays 
an important role in tumor development and progression62. 
The PAR4 protein seems to be overexpressed in the 
majority NSCLC tissues and this overexpression was 
associated with a shorter 3-year survival63.
Hypomethylation of the F2RL3 gene induces an 
enhanced expression of the protein PAR4. Thus, the risk of 
cancer increased with the decreasing methylation intensity. 
There was a significant difference in methylation between 
former smokers and current ones. Former smokers showed 
intermediate methylation intensity when compared to the 
current ones. Both hyper and hypomethylation are more 
prominent in older individuals (65 years and above), 
what can restrain the use of the DNA methylation as a 
biomarker61.
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From previous studies, it seems that the association 
of changes in genes methylation and the development of 
cancer is more relevant when found in the tumor cells. The 
use of blood cells in both studies turns this method less 
specific and sensible, making it less useful in a clinical set.
Another study about methylation was made by 
Greenberg et al.64 As many genes related to cell cycle can be 
methylated, it would be difficult to study each one and this 
would reduce sensitivity of one possible test. By analyzing 
S-adenosylmethionine (AdoMet), which is a component of 
the enzymatic pathway for DNA methylation, it would be 
possible to identify more alterations64.
This study measured AdoMet levels in three groups 
of patients: lung cancer, high risk smokers and healthy 
nonsmokers, also comparing their CT scans. AdoMet 
levels were significantly higher in serum from patients 
who have cancer as compared to high risk smokers with 
small noncalcified nodules. These findings suggest that 
using AdoMet levels could help distinguishing suspect and 
benign nodules in a CT scan, leading to previous diagnosis 
of lung cancer.
Telomere length
Telomere length has been directly connected with 
carcinogenesis, since telomerases are more expressed in 
cancer cells, allowing them to keep an unlimited capacity 
of proliferation65.
Seow et al. described a strong association between 
the telomere length in blood leukocytes and the presence 
of lung cancer66. This association was more evident in 
adenocarcinomas, particularly among females.
The limitation of using this biomarker is related to 
its lack of specificity. Telomere length is associated with 
carcinogenesis in every tissue, not only lung. Therefore, 
its use as a biomarker should be allied to other markers 
that are more specific to lung carcinogenesis.  Also, the 
smoking history wasn’t relevant in this study.
DISCUSSION
 
The probability of cure for patients with lung cancer 
is directly related to the ability to detect the disease in early 
stages, when both surgical and chemotherapy are more 
effective. Therefore, early detection is crucial, particularly 
in patients at high risk, like smokers2,3,17.
Unfortunately, the available methods are not 
sensible or specific enough to identify early lesions with the 
necessary accuracy. Actual guidelines rely heavily on the 
ability of low dose computed tomography to detect small 
nodules that may be lung tumors7. The main problem of 
this approach is the large number of false-positive exams 
or overdiagnosis, leading to invasive procedures and, 
consequently, increased risks to the patients17,19.
New tests are necessary and serum biomarkers of 
lung cancer would be ideal tools to screening large number 
of individuals.
In this review, we listed several potential candidates 
as serum biomarkers for early detection of lung cancer in 
high-risk patients (Table 1). Some of these articles were 
discussed in more detail above. There are several candidates 
to perform this task, however, none seems to possess all 
the necessary attributes.
Looking at the actual guidelines, there are two points 
where serum biomarkers could be more relevant.
First in selecting patients who could be at higher 
risk of developing lung cancer. Currently, these patients are 
submitted to LDCT annually, what leads to an enhanced 
chance of false-positive exams, besides all the risks of 
radiation and the costs of the exams17, 19. At this step of 
screening, serum tests should be very sensitive, since our 
goal would be to recognize all patients at risk of disease 
and submit them to more specific tests.
Serum biomarkers like NNAL52, that detect high 
exposure to cigarette smoke or Pro-Surfactant Protein B38, 
that is related with early stages of lung cancer development, 
could be useful tools to sort patients that would need more 
frequent or more complex exams.
A second point that serum biomarkers can improve 
the guidelines is to differentiate between benign and 
cancerous nodules. Nowadays, once a pulmonary solid 
nodule is detected, patient is submitted to an invasive 
procedure (biopsy) or a new exam is performed after 
some time.
Circulating substances like insulin growth factor 
binding protein 331,32 or the already cited Pro-Surfactant 
Protein B35,36,37 could help to identify the nature of the solid 
nodule, improving specificity of LDCT.
Given the important role of inflammation in 
lung cancer development67, the serum levels of some 
inflammatory mediators (CRP, Pentraxin, EMAP, etc.) 
could be useful to discriminate between lung cancer and 
more benign nodules.
CONCLUSION
Unfortunately, no single biomarker seems to be 
able to identify patients at risk to develop lung cancer, or 
to differentiate malign nodules from benign ones. 
However, some of the serum biomarkers described 
above appear to be promising, particularly when used in 
conjunction with other methods, like LDCT.
Large populational studies are yet needed to 
explore the usefulness of serum biomarkers for lung cancer 
diagnosis.  
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